Kaléo Pharmaceutical Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kaléo Pharmaceutical Inc.
REMS Integration Into Electronic Health Records To Be Tested By US FDA In Software Pilot
The prototype pulls information from the electronic record to fill out enrollment and other forms, but stakeholders say it must work for most, if not all, REMS drugs in order to be widely used.
Ohio Study Shows Access To Naloxone Soars Without Rx Requirement
JAMA study finds that removing Rx requirement for naloxone in Ohio resulted in a 2,328% increase in orders of the drug dispensed since 2015. Michael Hufford, CEO of a company working on an OTC switch for a naloxone nasal spray, says the results show urgent need for a low-cost OTC product.
US FDA's Words Matter: Sharpless Says Injectable Naloxone OK For Community Distribution
The acting commissioner's statement is intended to clarify "persistent misunderstanding" about the label for the opioid overdose rescue medication's injectable formulation.
FDA Prioritizes Reviews Of Opioid Overdose ANDAs
Opioid overdose treatments containing naloxone or nalmefene are now eligible for expedited ANDA review in a bid by the FDA to improve patient access.
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Intelliject, Inc.
- IJ Therapeutics
- Kaléo, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.